Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | VDR | P11473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL505553 | 0.85 | GRM5 (0.66) | GRM5GPR119KCNH2 | |
| SCHEMBL10250136 | 0.82 | GRM5 (0.52) | GRM5GPR119 | |
| SCHEMBL10249974 | 0.78 | GRM5 (0.73) | GRM5 | |
| SCHEMBL10249995 | 0.78 | GRM5 (0.60) | GRM5PDGFRBKDR | |
| SCHEMBL10250129 | 0.78 | GRM5 (0.50) | GRM5GPR119ADRB1PDGFRBKDR | |
| SCHEMBL10250329 | 0.76 | GRM5 (0.56) | GRM5KCNH2PDGFRBKDR | |
| SCHEMBL10250266 | 0.75 | GRM5 (0.48) | GRM5GPR119PDGFRBKDR | |
| SCHEMBL10250511 | 0.73 | GPR119 (0.35) | GPR119 | |
| SCHEMBL10250260 | 0.72 | GRM5 (0.49) | GRM5KCNH2ADRB1PDGFRBKDR | |
| SCHEMBL10250406 | 0.72 | GRM5 (0.64) | GRM5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | GRM5 1/4885GPR119 94/4885KCNH2 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.